Aethlon Medical

Intangible assets: The Hemopurifier platform is protected by patents and trade secrets and holds FDA Breakthrough Device designation for two independent indications: treatment of advanced or metastatic cancer unresponsive to or intolerant of standard of care, and treatment of life‑threatening viruses not addressed with approved therapies.

The company reports new patents in the U.S. and Europe around coronavirus-related conditions extending into the 2040s. These are meaningful intangible assets but do not by themselves ensure approval, reimbursement, or adoption.

Switching costs: If ever approved, the device integrates with existing dialysis infrastructure, implying low to moderate switching costs at the site level. In practice, switching costs will be driven by clinical guidelines and payer coverage, which require strong evidence not yet available. Network effects: None.

The product is a single‑use therapeutic cartridge with no platform network externalities. Cost advantages and efficient scale: No demonstrated manufacturing cost advantage versus other hemoadsorption approaches.

The addressable markets could be large in oncology and outbreaks, but efficient scale is not evident before compelling outcomes and reimbursement. Supplier concentration (Medica S.p.A. base cartridge, pending second source for a key component) weakens durability.

Durability risk: Rapid advances in oncology and infectious disease care, plus stringent device PMA pathways, threaten moat formation. FDA’s revocation of another hemoadsorption device’s EUA highlights demanding regulatory standards.